Touchlight’s cell-free, enzymatic dbDNA manufacturing platform underpins the NEOVACC Phase I trial led… The post Touchlight’s doggybone™ DNA (dbDNA™) technology enables first UK patient dosing in pioneering personalised lung cancer vaccine trial appeared first on Touchlight .